(Q33629410)

28 July 2017

0 references

1 reference

title

A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome (English)

1 reference

28 July 2017

1 reference

irritable bowel syndrome

1 reference

Mohammad Abdollahi

3

0 references

author name string

Mahnaz Darvish-Damavandi

series ordinal

1

1 reference

28 July 2017

Shekoufeh Nikfar

series ordinal

2

1 reference

28 July 2017

language of work or name

English

0 references

publication date

1 February 2010

1 reference

World Journal of Gastroenterology

28 July 2017

published in

1 reference

28 July 2017

volume

16

1 reference

28 July 2017

issue

5

1 reference

28 July 2017

page(s)

547-553

1 reference

Pathogenesis and management of irritable bowel syndrome.

28 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816265

Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816265

Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816265

Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816265

Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816265

Systematic review: the safety and tolerability of pharmacological agents for treatment of irritable bowel syndrome--a European perspective

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816265

The placebo effect in irritable bowel syndrome trials: a meta-analysis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816265

Drug therapy options for patients with irritable bowel syndrome

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816265

Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816265

A three-part controlled study of trimebutine in the treatment of irritable colon syndrome

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816265

Comparison of the therapeutic effect of wheat bran, mebeverine and placebo in patients with the irritable bowel syndrome

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816265

The irritable colon syndrome. New therapeutic possibilities in the treatment of a frequent syndrome

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816265

Determination of placebo effect in irritable bowel syndrome

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816265

The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816265

Effect of a calcium channel blocker and antispasmodic in diarrhoea-predominant irritable bowel syndrome

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816265

Comparison of two different formulations of mebeverine hydrochloride in irritable bowel syndrome

30 October 2018

1 reference

12 December 2020

Physiological and clinical assessment of the effect of the musculotropic agent mebeverine on the human colon

1 reference

12 December 2020

Mebeverine, An Effective Agent in the Irritable Colon Syndrome

1 reference

12 December 2020

Mebeverine in patients with the irritable colon syndrome: double blind study

1 reference

12 December 2020

Comparison of various treatments for irritable bowel syndrome

1 reference

12 December 2020

Controlled clinical study of the action of mebeverine hydrochloride in the treatment of irritable colon

1 reference

12 December 2020

The treatment of irritable bowel syndrome. Two doses of mebeverine compared

1 reference

12 December 2020

Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome

1 reference

12 December 2020

A double-blind crossover comparison study of the safety and efficacy of mebeverine with mebeverine sustained release in the treatment of irritable bowel syndrome

1 reference

12 December 2020

Identifiers

DOI

10.3748/WJG.V16.I5.547

1 reference

28 July 2017

1 reference

28 July 2017

1 reference